Former CMS Administrator to work on defending ACA

The now-ex-administrator of CMS, Andy Slavitt, plans on staying in Washington, D.C., part-time to help save at least some parts of the Affordable Care Act (ACA), according to an exclusive interview with POLITICO.

Slavitt says while he’ll spend time in his native Minnesota, as well, he won’t be returning to his former job at health consultant Optum. That doesn’t mean he’ll become a lobbyist or seek any elected office, but he’s promising to work with lawmakers, hospital executives and healthcare providers to try modifying the ACA rather than fully eliminating it.

The interview goes further into his post-CMS plans and favored healthcare reforms than his final speech to agency employees.

He acknowledges the current Republican control of government makes it likely more “free market ideas” will have to be included in any ACA fix, but he’s open to discussing certain proposals, even one he calls “a terrible idea,” that being high-risk pools.

“If we are having a rational debate over risk pools versus reinsurance, that’s where Washington should be on policy issues,” Slavitt said.

Read the full article below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.